Cancer Cell-Intrinsic Programs That Shape Tumor Immune Ecosystems

The tumor immune microenvironment (TIME) is a highly dynamic ecosystem that critically influences tumor progression, metastatic dissemination, and therapeutic responsiveness. Classical models of tumor biology have long been framed by the “seed and soil” paradigm, in which malignant cells represent passive “seeds” growing within a permissive or restrictive microenvironmental “soil.” However, accumulating evidence indicates that this framework is incomplete. Tumor cells are not merely shaped by their environment but actively orchestrate the immune landscape through intrinsic molecular programs. In this review, we synthesize emerging evidence supporting a revised paradigm in which cancer cell-intrinsic drivers, including oncogenic signaling pathways, metabolic reprogramming, and epigenetic alterations, act as central regulators of the TIME. These intrinsic programs enable malignant cells to rewire immune surveillance by suppressing cytotoxic lymphocyte function, promoting the recruitment and polarization of immunosuppressive myeloid populations, and establishing metabolic and structural barriers that limit effective antitumor immunity. Recent technological advances, particularly single-cell transcriptomics, spatially resolved profiling, and multi-omic approaches, have provided unprecedented insight into how these tumor-cell programs reshape immune architecture across spatial niches within tumors. We discuss how these mechanisms collectively generate immunosuppressive microenvironments that underlie resistance to immune checkpoint blockade and other immunotherapies. Finally, we highlight emerging therapeutic strategies aimed at targeting cancer cell-intrinsic drivers to reprogram the TIME, emphasizing the potential of rational combination approaches that simultaneously modulate tumor signaling, metabolism, and immune activation. Understanding cancer cells as active architects of their immune ecosystem provides a conceptual framework for the next generation of precision immunotherapies.